BeyondSpring Inc. (BYSI)

NASDAQ: BYSI · IEX Real-Time Price · USD
3.630
+0.020 (0.55%)
At close: Mar 27, 2024, 4:00 PM
3.500
-0.130 (-3.58%)
Pre-market: Mar 28, 2024, 8:10 AM EDT
0.55%
Market Cap 141.63M
Revenue (ttm) 1.55M
Net Income (ttm) -27.51M
Shares Out 39.02M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE 10.54
Dividend n/a
Ex-Dividend Date n/a
Volume 64,095
Open 3.650
Previous Close 3.610
Day's Range 3.500 - 3.690
52-Week Range 0.653 - 4.000
Beta -0.05
Analysts Buy
Price Target 1.25 (-65.56%)
Earnings Date Apr 14, 2022

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of no... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2017
Employees 73
Stock Exchange NASDAQ
Ticker Symbol BYSI
Full Company Profile

Financial Performance

In 2022, BeyondSpring's revenue was $1.35 million, a change of 0.00% compared to the previous year's $1.35 million. Losses were -$33.28 million, -48.15% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for BYSI stock is "Buy" and the 12-month stock price forecast is $1.25.

Price Target
$1.25
(-65.56% downside)
Analyst Consensus: Buy
Stock Forecasts

News

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innov...

3 days ago - GlobeNewsWire

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking tech...

2 months ago - GlobeNewsWire

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking tech...

3 months ago - GlobeNewsWire

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking tech...

5 months ago - GlobeNewsWire

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law Schools, Brings Five Decades of Experience in Global Health, Law, Governance, and International Busin...

5 months ago - GlobeNewsWire

BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking tec...

6 months ago - GlobeNewsWire

BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking tec...

7 months ago - GlobeNewsWire

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking techn...

11 months ago - GlobeNewsWire

BeyondSpring Files 2022 Annual Report on Form 20-F

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc.  (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical-stage global biopharmaceutical company focused on using its novel technolog...

1 year ago - GlobeNewsWire

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

- SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration - BeyondSpring Completed Enrollment of Three Investigator-Initiated Trials (IIT) with Plinabulin in t...

1 year ago - GlobeNewsWire

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc.  (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative canc...

1 year ago - GlobeNewsWire

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cance...

1 year ago - GlobeNewsWire

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

Plinabulin rapidly (within 24 hours) mitigates chemotherapy-induced myelosuppression by protecting bone marrow granulocyte-monocyte progenitor (GMP) stem cells Plinabulin rapidly (within 24 hours) mit...

1 year ago - GlobeNewsWire

BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

Plinabulin was well tolerated and only one out of the 10 patients enrolled had non-engraftment related neutropenic fevers or febrile neutropenia (FN) with the plinabulin/pegfilgrastim combination Plin...

1 year ago - GlobeNewsWire

BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

NEW YORK, May 27, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer...

1 year ago - GlobeNewsWire

BeyondSpring Files 2021 Annual Report on Form 20-F

NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative canc...

2 years ago - GlobeNewsWire

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

- Company to host call today, April 14, 2022 at 8:00 am ET

2 years ago - GlobeNewsWire

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer ther...

2 years ago - GlobeNewsWire

BeyondSpring Cuts On-Third Of Its Workforce

BeyondSpring Inc (NASDAQ: BYSI) plans to reduce its U.S. workforce by 35%, including reassignment of certain personnel to subsidiaries, which is expected to result in cost savings that will extend the...

2 years ago - Benzinga

BeyondSpring Announces Organizational Streamlining

NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeu...

2 years ago - GlobeNewsWire

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant re...

2 years ago - GlobeNewsWire

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

BeyondSpring Inc (NASDAQ: BYSI) announced new data highlighting the mechanism of action of plinabulin in preventing chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) A...

2 years ago - Benzinga

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeu...

2 years ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors BeyondSpring Inc. - BYSI

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BeyondSpring Inc. ("BeyondSpring" or the "Company") (NASDAQ: BYSI). Such investors are advised t...

2 years ago - PRNewsWire

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeu...

2 years ago - GlobeNewsWire